Remicade Becomes First Anti-TNF Biologic Therapy to Treat 1 Million Patients

Centocor, Inc., Schering-Plough Corporation and Mitsubishi Tanabe Pharma Corporation announced that an estimated 1 million patients have now been treated with Remicade (infliximab), the leading antitumor necrosis factor (TNF)-alpha therapy worldwide.
Earthtimes